Explore how tumor necrosis factor inhibitors (TNFis) may reduce cardiovascular risks in patients with inflammatory arthritis, ...

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first participant ...

No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has ...

Contemporary estrogen-progestin contraceptives are associated with an increased risk for ischemic stroke and myocardial infarction.

Researchers used feedback from patient focus groups to develop tools and recommendations for shared anticoagulant ...